Profusa Raises $714K Via Convertible Note, Moves to Exchange $6.14M Debt for Preferred With Ascent
Profusa raised $714,285.72 via a senior secured convertible note at 7% interest, maturing in 2027, with a $1.07 conversion price. It also agreed to exchange $6.14M in debt for Series A Preferred Stock, implying a $4.28 conversion price, to simplify its capital structure.
How this was made
The 30-second read
Why it matters
The new convertible note and preferred exchange reduce existing debt but introduce convertible preferred equity, affecting share count.
Market read
Primary disclosure of a small‑scale financing event for a micro‑cap biotech; limited trading relevance.
What to watch
Potential covenant restrictions or covenants not disclosed could affect future financing flexibility.
Background
Profusa is a biotech company developing diagnostic platforms; recent financing aims to streamline its capital structure.
Ticker impact
Profusa issued a $714,285 senior secured convertible note and exchanged $6.14M of existing notes for Series A Preferred, reducing debt.
Potential slight upside as debt is reduced, but conversion terms may cap upside.
Small‑scale capital raise for a micro‑cap; impact limited to liquidity and dilution considerations.
Market effects
May signal continued financing activity in the biotech financing niche.
Limited to US micro‑cap biotech segment.
Minimal global impact.
Counterpoint
The note's conversion price could lead to future dilution if the stock underperforms.
Key entities
- CompanyProfusa, Inc.
Biotech firm issuing the convertible note.
- InvestorAscent Partners Fund
Counterparty to the financing agreements.